News

Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

The deal signed last month by the US-based Gilead Sciences and Galapagos has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 by the US Federal Trade

In the Phase 2 portion of the Phase 2/3 study, a multicenter, randomized double-blind trial, all patients received docetaxel 75 mg/m2 on Day 1. Patients were randomly assigned

The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth

The FDA has advised Seelos that it may proceed with the proposed clinical trial SLS-005-201 for Mucopolysaccharidosis type III (Sanfilippo syndrome). “We are very pleased to have received

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the

Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based

The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient